Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Study of Pembrolizumab and Eribulin in Patients With HR-positive/HER2-negative Metastatic Breast Cancer Previously Treated With Anthracyclines and Taxanes

NCT03222856 is registered in ClinicalTrials.gov with MedSIR as lead sponsor.

NCT NCT03222856
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03222856 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Study of Pembrolizumab and Eribulin in Patients With HR-positive/HER2-negative Metastatic Breast Cancer Previously Treated With Anthracyclines and Taxanes
Lead sponsor
MedSIR
Phase
Phase 2
Overall status
Completed
Start date
December 14, 2017
Completion date
December 23, 2020
Enrollment
44 (actual)
Sites
11

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer